Arch Biopartners Inc. (TSXV: ARCH) is one of this year's TSX Venture 50 companies — the company focuses on the development of innovative technologies.
Arch Biopartners' portfolio of technology includes AB569 which is a new drug candidate for treating antibiotic-resistant bacterial infections, primarily in the lungs and urinary tract.
The company also has MetaBlok, which is a new drug candidate targeting sepsis, cancer metastasis and inflammation based diseases, and Arch Inflammation which is a novel treatment for chronic kidney and bowel diseases caused by non-infectious inflammation.
The 2019 TSX Venture 50 is a ranking of top performers on the TSX Venture Exchange over the last year. The ranking is comprised of 10 companies from each of the five industry sectors, and they were selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume.
For the full 2019 TSX Venture 50 ranking, methodology and profile videos of companies included in the ranking, visit: www.tsx.com/venture50